Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from SynAct Pharma AB ( (SE:SYNACT) ).
SynAct Pharma AB’s Board of Directors has proposed an authorization for the acquisition and transfer of the company’s own shares, subject to approval at an Extraordinary General Meeting. This move aims to enhance the company’s capital structure, potentially increasing shareholder value and providing flexibility for future business transactions. The proposal includes a buy-back program with a maximum purchase value of SEK 10 million, and the company is positioning itself for strategic opportunities ahead of its ADVANCE phase 2b-study results expected in early 2026.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company listed on Nasdaq Stockholm, specializing in the resolution of inflammation through the selective activation of the melanocortin system. The company offers a range of oral and injectable selective melanocortin agonists designed to induce anti-inflammatory and inflammation resolution activity, aiding patients in achieving immune balance.
YTD Price Performance: 134.24%
Average Trading Volume: 170,633
Technical Sentiment Signal: Hold
Current Market Cap: SEK1.12B
Find detailed analytics on SYNACT stock on TipRanks’ Stock Analysis page.